Han forlod Novo for at bygge nyt fedmeselskab op fra bunden: “I sidste ende føles det helt rigtigt”
Alveus Therapeutics Announces Second and Final Closing of Oversubscribed Series A, Bringing Total Financing to $197 Million to Advance Next-Generation Therapies for Obesity and Metabolic Diseases
Alveus raises $197M Series A to advance obesity and metabolic disease pipeline
Why GIPR antagonism could reshape the next wave of weight-loss drugs
ALV-100 Phase 2 Trial Doses First Patient in Long-Term Weight Maintenance Study
Alveus Presents Preclinical Amylin Portfolio Data at Metabolic Disease Congress